Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076430 | 0.91 | MAOB (0.52) | MAOBTACR1ALDH1A1LMNAALOX5 | |
| SCHEMBL10076433 | 0.84 | MAOB (0.58) | MAOBMAOATACR1ALDH1A1LMNA | |
| SCHEMBL10076432 | 0.81 | MAOB (0.38) | MAOBPPARGPPARA | |
| SCHEMBL16552350 | 0.73 | MAOB (1.00) | MAOBMAOAALOX5 | |
| SCHEMBL14077134 | 0.70 | MAOB (0.56) | MAOBTACR1 | |
| SCHEMBL17680423 | 0.69 | CA1 (0.58) | TACR1PPARGPPARA | |
| SCHEMBL19227378 | 0.67 | CA1 (0.64) | TACR1 | |
| SCHEMBL2477506 | 0.67 | MAOB (0.53) | MAOBMAOALMNA | |
| SCHEMBL2477505 | 0.67 | MAOB (0.53) | MAOBMAOALMNA | |
| SCHEMBL2477504 | 0.67 | MAOB (0.53) | MAOBMAOALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2012-01-19 | — | — | US | disclosed |
| US-7956220-B2 | MAO-B inhibitors useful for treating obesity | JENRIN DISCOVERY (US) | 2011-06-07 | — | — | US | disclosed |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885MAOA 2/4885TACR1 867/4885 |
| US-20070004683-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885MAOA 2/4885TACR1 867/4885 |
| US-20140155355-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885MAOA 2/4885TACR1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.